Skip over navigation
l'Hôpital
Recherche
Soutenez-nous
Ottawa Hospital Research Institute
Accueil
English
Directions et cartes
Nous joindre
Au sujet de l’IRHO
Vision et orientations stratégiques
Message du PDG
L'équipe de direction
Rapports annuels
Installations
La gestion des données de recherche
Équité, diversité et inclusion
Notre recherche
Priorités, programmes et maladies
Profils de chercheurs
Réseaux de recherche nationaux
Publications scientifiques
Bourses et prix de recherche
Transfert de la technologie
Innovation responsable
Étudiants et stagiaires postdoctoraux
Nouvelles et activités
Nouvelles
Séminaires & Activités
Carrières
Pour les patients
News & Events
Accueil
>
Nouvelles et activités
>
Nouvelles
Bookmark or Share
Option d'affichage
Option d'affichage
+
Augmentez
/
-
Diminuez
taille de police
Contraste élevé
Imprimante facile
Nouvelles
Séminaires & Activités
Newsroom
Exploiting the Achilles’ heel of a severe form of childhood leukemia
mars 19, 2018
Drs.
Marjorie Brand
and
Jean-François Couture
were awarded $588,000 from the Canadian Institutes of Health Research to investigate a new treatment approach for one of the most aggressive forms of childhood leukemia. The current treatment for T-cell Acute Lymphoblastic Leukemia (T-ALL) is chemotherapy, with side effects that include secondary cancers later in life and stunted growth. If the cancer returns after treatment, patients usually die soon after. Dr. Brand’s research team
previously reported
that a common form of T-ALL called TAL-1 has a weak spot: It needs a partner in crime, an enzyme called UTX, to trigger the production of cancer cells. So when the team used a compound called GSK-J4 to turn off UTX, it completely stopped the growth of TAL-1 type cancer cells. This new funding will allow them to explore treatment methods for T-ALL that exploit this weakness, which may lead to therapies that are less toxic and more effective.
Dr. Marjorie Brand’s research is possible because of generous support for
Regenerative Medicine Research
at The Ottawa Hospital.
The Ottawa Hospital: Inspired by research. Driven by compassion
The Ottawa Hospital is one of Canada’s largest learning and research hospitals with over 1,100 beds, approximately 12,000 staff and an annual budget of over $1.2 billion. Our focus on research and learning helps us develop new and innovative ways to treat patients and improve care. As a multi-campus hospital, affiliated with the University of Ottawa, we deliver specialized care to the Eastern Ontario region, but our techniques and research discoveries are adopted around the world. We engage the community at all levels to support our vision for better patient care. See www.ohri.ca for more information about research at The Ottawa Hospital.
University of Ottawa: —A crossroads of cultures and ideas
The University of Ottawa is home to over 50,000 students, faculty and staff, who live, work and study in both French and English. Our campus is a crossroads of cultures and ideas, where bold minds come together to inspire game-changing ideas. We are one of Canada’s top 10 research universities—our professors and researchers explore new approaches to today’s challenges. One of a handful of Canadian universities ranked among the top 200 in the world, we attract exceptional thinkers and welcome diverse perspectives from across the globe. www.uottawa.ca
Media Contact
Amelia Buchanan
Senior Communication Specialist
Ottawa Hospital Research Institute
Office: 613-798-5555 x 73687
Cell: 613-297-8315
ambuchanan@ohri.ca
Tags:
Blood cancer
,
Cancer
,
Drug development